Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, 1795:TT) today announced that Alvogen US received a decision from the United States District Court for the District of Delaware that Alvogen prevailed in challenging US Patent No. 8,784,888, the only remaining patent in suit, covering UCERIS (Budesonide ER) tablets marketed as a brand product by Valeant International Pharmaceuticals (“Valeant”). This is one of the products under strategic alliance between Alvogen US and Lotus. The court determined that the asserted claims of this patent are not infringed, and therefore Alvogen US and Lotus will proceed with ANDA related preparations. Meanwhile, the Company is prepared if Valeant appeals.